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OBJECTIVES: To present nationally representative estimates of the impact of 
cancer survivorship on medical expenditures and lost productivity among adults 
in the United States. METHODS: Using the 2008-2010 Medical Expenditure Panel 
Survey we identified 4,960 cancer survivors and 64,431 individuals without a 
history of cancer aged ≥18 years. Direct medical costs were measured using 
annual health care expenditures and examined by source of payment and 
service type. Indirect morbidity costs were estimated from the lost productivity 
due to health-related unemployment, missed work days, and lost household 
productivity. We evaluated the economic burden of cancer survivorship by 
estimating the excess costs among cancer survivors compared with individuals 
without a history of cancer using multivariable regression models stratified by 
age (18-64 and ≥65 years) while controlling for age, gender, education, and 
comorbidities. RESULTS: In 2008-2010, the annual excess economic burden of 
cancer survivorship was $7,631 per cancer survivor aged 18-64 years and $5,445 
per survivor aged ≥65 years. Excess direct medical expenditures comprised the 
largest share, with excess annual medical expenditures of $5,570 and $4,683 
among cancer survivors aged 18-64 years and ≥65 years, respectively. 
Ambulatory care accounted for the largest share of medical expenditures in both 
groups. The largest source of payment was private health insurance for cancer 
survivors aged 18-64 years, and Medicare for cancer survivors aged ≥65 years. 
Cancer survivors aged 18-64 years incurred an excess annual productivity loss of 
$2,061 per individual while cancer survivors aged ≥65 years reported an excess 
annual lost productivity of $762 per individual. CONCLUSIONS: The economic 
burden of cancer survivorship is substantial, resulting in excess health care 
expenditures and lost productivity costs compared with individuals without a 
history of cancer. Efforts to reduce the economic burden caused by cancer will be 
increasingly important given the growing population of cancer survivors.  
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OBJECTIVES: To estimate the incremental health care costs associated with 
adverse events (AEs) among metastatic melanoma (MM) patients treated with 
seven commonly used therapies. METHODS: Retrospective health care claims 
from the Marketscan® commercial and Medicare supplemental databases were 
examined from June 1, 2004 to April 30, 2012. Patients included those ≥18 years 
who had diagnosed melanoma (ICD-9 code: 172.xx) with at least one diagnosis of 
metastasis within 30 days prior to or 60 days after any melanoma diagnosis, and 
≥ one claim for any of the following MM treatments: paclitaxel, vemurafenib, 
ipilimumab, dacarbazine, temozolomide, high dose interleukin-2, or interferon 
alpha. AE categories of interest included cardiovascular, CNS/psychiatric, 
metabolic disorders, gastrointestinal, hemic/lymphatic disorders, pain, and 
skin/subcutaneous events that occurred after initiation of therapy. Health care 
encounters for AEs were based on ICD-9-CM diagnosis/procedure codes on 
health care claims. The incremental cost per AE was determined by comparing 
the 30-day expenditures in patients with the event to patients without the event 
based on a 30-day shadow event date. Drug costs of the MM therapies were 
excluded from the analysis. Multivariate generalized linear models (GLM) with a 
log-link function and gamma distribution were utilized to control for differences 
in baseline characteristics between groups. RESULTS: A totla of 2621 MM 
patients were included in this analysis. Mean age was 56.0 years (SD: 13.0), 64% 
were male and 24% had a diagnosis of primary or secondary brain cancer at the 
time of MM diagnosis. The GLM-based estimate of 30-day incremental costs by 
AE category were: metabolic, $9,135 (95% CI: $6,404-$12,392); hemic/lymphatic, 
$8,450 ($6,528-$10,633); cardiovascular, $6,476 ($4,667-$8,541); gastrointestinal, 
$6,338 ($4,740-$8,122); skin/subcutaneous, -$900 (-$1,899- $237); CNS/psychiatric, 
$5,903 ($3,842-8,313); and pain, $5,078 ($3,392-$7,012). CONCLUSIONS: The 
incremental costs associated with AEs therapies to treat MM are substantial. 
New approaches to prevent and/or better manage these events may reduce 
overall health care costs.  
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OBJECTIVES: To characterize real-world medical resource utilization and costs 
following initiation of anti-cancer treatments for patients with Stage IB-IV Non-
Small Cell Lung Cancer (NSCLC). METHODS: A retrospective, longitudinal, open-
cohort study design was chosen using Medicare linked Surveillance 
Epidemiology and End Results (SEER) data. All Medicare-eligible patients in the 
SEER registry who were diagnosed with NSCLC during 2005–2007 and treated 
with anti-cancer therapy were identified. The observation period spanned from 
NSCLC diagnosis through the earliest date of end of anti-cancer therapy, data 
end date, or death. All-cause and NSCLC-related utilization and costs were 
reported, stratified by hospitalization, emergency room (ER), and outpatient 
visits. Results were stratified by patients with non-advanced cancer (Stages IB-
IIIA) and advanced cancer (Stages IIIB-IV). Pharmacy costs were reported for 
patients diagnosed with NSCLC in 2007. RESULTS: The study population 
consisted of 6,365 patients; mean (SD) age was 73.7 (5.4) years, 54% were males, 
and median follow-up was 351 days. The all-cause rate per patient per month 
(PPPM) was 0.14, 0.10, and 4.08; NSCLC-related PPPM rate was 0.12, 0.05, and 2.86 
for hospitalization, ER, and outpatient, respectively. The median monthly length 
of stay (days) for hospitalization was 1.25 for all-cause and 1.0 for NSCLC-related 
stays. The mean all-cause PPPM costs were $4,989 (hospitalization: $2,278, ER: 
$54, outpatient: $2,657). The mean NSCLC-related PPPM costs were $4,032 
(hospitalization: $1,721, ER: $23, outpatient: $2,288). The mean all-cause PPPM 
costs were $3,805 ($2,873 NSCLC-related) for patients with non-advanced cancer 
and $5,822 ($4,847 NSCLC-related) for patients with advanced cancer. All-cause 
PPPM prescription drug costs were $560. CONCLUSIONS: The SEER-Medicare 
database analysis found that in Stage IB-IV NSCLC patients, NSCLC-related costs 
accounted for over 80% of all health care costs while patients were on anti-
cancer therapies. Higher costs were incurred by patients diagnosed with 
advanced NSCLC as compared to patients diagnosed with non-advanced disease.  
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OBJECTIVES: Despite major advances, resistance and intolerance continue to be 
a significant challenge in the management of CML. This study evaluated the real-
world resource use and costs associated with CML treatment failure with 
dasatinib or nilotinib (defined as treatment switch or discontinuation) from a US 
payer perspective. METHODS: This was a retrospective study using the IMS 
PharMetrics health plan claims database from July 2006-June 2011. Adult patients 
with CML diagnosis (ICD-9 205.1x) with ≥1 fill of dasatinib or nilotinib were 
selected. Failure was defined as a switch to another tyrosine kinase inhibitor 
(TKI) or a gap in index TKI >90 days. Direct medical resource use and costs (2011 
USD) were measured for those with 6 months of continuous enrollment post-
failure, including all-cause medical and pharmacy costs. RESULTS: 608 CML 
patients were identified initiating dasatinib or nilotinib, of which 290 
experienced treatment failure. Of these, 192 had 6 months of continuous 
enrollment post-failure. Average age was 57.5 years and 55.7% were female. 
Mean 6-month costs post-failure were $79,996 (median $33,100), with inpatient 
costs comprising 54.4%, followed by pharmacy (23.1%) and outpatient (22.2%). 
During the 6 months post-failure, one-third of patients had at least one 
hospitalization (median 12 days) with leukemia being the most frequent primary 
diagnosis for hospitalization, 22% had an emergency room visit, 96% had 
physician office visits (median 11 visits), with a median of 27 lab tests and 20 
prescription fills per person (median 16 non-TKI fills). CONCLUSIONS: The 6-
month economic burden of failure from nilotinib and dasatinib is substantial and 
is largely due to the disease. The availability of new agents to effectively manage 
this hard-to-treat population has the potential to improve costs of care by 
preventing disease progression.  
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OBJECTIVES: To determine the usage and costs of oral cancer treatment in 
elderly Medicare Part D beneficiaries. METHODS: A cross-sectional retrospective 
study was conducted using a 5% random sample of 2008 Medicare beneficiaries. 
The study sample included all members of this group who: 1) were 65 years of 
age and older and 2) filled at least one prescription for imatinib, erlotinib, 
anastrozole, letrozole, or thalidomide.We examined the average costs patients 
paid per day, the cost that the Part D plan paid per day, and total cost for the 
entire year for each drug. We determined the percentage of enrollees who 
entered the Part D coverage gap, the time, and duration that they fell into the 
coverage gap. RESULTS: Prescription drug subsidy was categorized in four 
groups: 1) Dual Eligible (DE); 2) full Low Income Subsidy (LIS); 3) partial LIS; and 4) 
no subsidy. Mean out-of-pocket (OOP) costs per day were between $0.03 and 
$0.09 for DE beneficiaries, between $0.04 and $0.22 for full LIS beneficiaries, 
between $1.17 and $6.34 for partial LIS beneficiaries,and between $2.92 and 
$36.83 for beneficiaries who did not receive a subsidy. About 99% of users of the 
more expensive drugs - imatinib, erlotinib and thalidomide - entered the 
coverage gap and the majority of these entered the coverage gap at the time of 
their first fill. In contrast, beneficiaries who filled the less expensive drugs - 
anastrozole and letrozole- entered the coverage gap later. Beneficiaries who used 
imatinib, erlotinib, or thalidomide spent approximately a month in the coverage 
gap. The majority of their time was spent in the catastrophic phase. 
CONCLUSIONS: Beneficiaries receiving subsidies had low OOP costs, averaging 
between $0.03 and $6.34 per day. Beneficiaries on the more expensive drugs and 
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OBJECTIVES: The rising costs of cancer care are a major focus for clinicians, 
payers and patients. This analysis describes changes in location of 
chemotherapy administration and reimbursement, highlighting areas for 
potential policy changes METHODS: Using the MarketScan©Research Databases, 
administrations of bevacizumab and trastuzumab were identified from January 
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1, 2005 through December 31, 2011 for patients with commercial or employer-
sponsored supplemental Medicare insurance. Bevacizumab claims were 
excluded if the claim had a diagnosis related to macular degeneration or other 
eye disease. Claims for both drugs were excluded from the payment analysis if 
the reimbursed amount was less than $100. All claims were identified as 
occurring in an office-based setting (OBS), an outpatient hospital setting (OHS) or 
other setting. RESULTS: The percent of bevacizumab claims occurring in OHS 
increased from 6 to 37% among Medicare claims, and from 15 to 42% among 
commercial claims from 2005 to 2011. For trastuzumab, the increases were 9 to 
33%, and 17 to 37% in Medicare and commercial claims, respectively. Median 
bevacizumab reimbursement increased 56% ($3000 to $4681) for OBS and 125% 
($3438 to $7739) for OHS from 2005 to 2011 in commercial claims. For Medicare 
claims, the increases were 88% ($2284 to $4284) and 111% (2284 to $4827) for OBS 
and OHS, respectively. For trastuzumab commercial claims, median 
reimbursement increased 47% ($2037 to $2996) and 88% ($2749 to $5171) for OBS 
and OHS; while for Medicare the increases were 68% ($1697 to $2854) and 67% 
($1704 to $2838), respectively. CONCLUSIONS: The shift in chemotherapy 
administration from OBS to OHS and related growth in reimbursement for 
outpatient hospital settings relative to office settings has implications for the 
growth in cancer costs over the past decade. Further research is warranted to 
understand the drivers of the shift in location and whether future policies should 
address reversing the shift.  
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OBJECTIVES: To analyze the cost of care in oncology inpatients in Brazilian 
private hospitals and their spending on medicine (chemotherapy and palliative 
care). METHODS: We selected patients who consume antineoplastic medicines 
in Orizon database (16 million lifes) within a 12-month period and analyzed their 
medical bills, appointments and hospitalizations (direct costs) and also 
medicines for palliative treatment. RESULTS: We identified 1244 patients who 
consume an annual average of R$ 6,342.51 in outpatient use of anticancer drugs 
per patient and their medical bills US$30,320.78 in expenses with a mean 
hospital stay of 4.60 days with 4, 48 consultations per patient to the cost of 
R$210.56 and the cost of medicines for palliation of R$6,277.16 (regulators of bone 
metabolism, corticosteroids, antidepressants, anti-inflammatories, diuretics, 
antiemetics, anticonvulsants, analgesics, vitamins and antispasmodics) 
CONCLUSIONS: The direct costs of cancer patients is not restricted only hospital 
infusions and their admissions, but also outpatient expenditures such as oral 
medications and palliative treatments.  
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OBJECTIVES: The prognosis of melanoma patients with brain metastases is poor, 
with median overall survival of approximately 4-5 months. This is the first study 
aiming at quantifying medical resources utilization and direct health care costs 
associated with brain metastases among metastatic melanoma patients in the 
U.S. METHODS: A retrospective pre-post design was implemented using data 
from the Truven MarketScan claims database (2000Q1-2011Q3). Patients with ≥1 
diagnosis of melanoma (ICD-9-CM: 172-173, 198.2), ≥1 diagnosis of brain 
metastases (ICD-9-CM: 198.3), and ≥18 years as of the first observed brain 
metastases diagnosis (index date) were identified. The pre-period was defined as 
the 6 months prior to the index date and post-period as the period following the 
index date up to the earliest of 12 months, recorded death, or loss to follow up. 
All-cause and brain metastasis-related medical resources and health care costs 
were compared on a per patient per month (PPPM) basis between the pre- and 
post-periods. RESULTS: The study population consisted of 6076 patients; mean 
(SD) age was 63.4 (13.4) years and 57.6% males. Significant differences were 
observed between the post- and pre-period in mean all-cause PPPM 
hospitalizations (0.21 vs. 0.08), emergency department visits (0.12 vs. 0.08), and 
outpatient visits (4.48 vs. 3.74) (p<.0001 for all). Similar results were found for 
brain metastasis-related hospitalizations (0.15 vs. 0.04), emergency department 
visits (0.02 vs. 0.01), and outpatient visits (2.00 vs. 1.17) (p<.0001 for all). 
Significant post- vs. pre-period differences were also observed in the PPPM all-
cause health care costs (total: $14,489 vs. $7,277; inpatient: $6,330 vs. $1,900; 
outpatient: $6,609 vs. $4,449; p<.0001 for all) and brain metastasis-related costs 
(total: $6,542 vs. $1,933; inpatient: $2,976 vs. $472; outpatient: $3,451 vs. $1,413; 
p<.0001 for all). CONCLUSIONS: The economic burden associated with brain 
metastases in melanoma is significant and underscores the need for newer 
therapies improving outcomes among these patients.  
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OBJECTIVES: Prolonged air leaks (PAL) lasting >5 days occur in up to 50% of all 
patients undergoing lung volume reduction surgery (LVRS); resulting in increased 
length of stay (LOS), patient morbidities, and health care costs. We sought to 
map care path options for the management of PAL following LVRS among 
emphysematous patients, and to report estimates of associated costs. 
METHODS: Peer-reviewed English language articles from January 2000 – 
September 2012 were searched using pre-identified terms. A typical care path for 
a male smoker with emphysema was mapped from diagnosis to removal of chest 
tube after LVRS. Parameters extracted from the identified articles were 
country/region, year, type of study, type of procedure [open vs. video-assisted 
thoracoscopic surgery (VATS)], number of patients, cost, LOS and complication 
rates. RESULTS: The care path captured treatment events from diagnosis of 
nodules to post-surgical follow up care. PAL treatment options included the 
Heimlich valve, autologous blood patch or both prior to discharge. Eleven studies 
reporting cost data for 4,945 VATS procedures and 18,033 open procedures were 
identified. LOS [3.0 – 17.3 days (VATS) versus 5.0 to 23.8 days (open)], hospital 
costs [US unadjusted: $10,084 to $23,826 (VATS) versus $12,119 - $25,125 (open)] 
and complication rates were lower for VATS versus open procedures. Similar 
cost differences were reported in Korea, Japan and China. Post-discharge care 
and cost of patients with PAL were driven by the utilization of home health care, 
increased pain management costs, more frequent doctor visits and delayed 
return to work. CONCLUSIONS: There is wide variability in the care path options 
associated with management of PAL and associated complications during LVRS 
in emphysema patients. VATS appears to have a positive health care utilization 
and cost advantage versus open procedures globally. Further analyses are 
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OBJECTIVES: To evaluate the cost-effectiveness of cabazitaxel in 2L metastatic 
castration resistant prostate cancer (mCRPC) patients who progressed after 
docetaxel (D) from the Swedish health care perspective in a subgroup of the 
TROPIC trial (NCT00417079) METHODS: A Markov cohort based cost effectiveness 
model was used. Transition rates between the health states representing mCRPC 
disease progression (stable, progression, death) were estimated based on 
progression of disease and survival rates from the TROPIC trial. The efficacy and 
safety data is based on the results of the TROPIC trial, which compares 
cabazitaxel plus prednisone to mitoxantrone plus prednisone in patients 
previously treated with docetaxel. Resource inputs were obtained from 
literature, hospital data and key opinion leaders. The subgroup is defined as 
those patients who initially responded to D but experienced disease progression 
<3 months since last D dose. At the time of the trial, the combination of 
Mitoxantrone (M) and Prednisone (P) was considered to be an appropriate second 
line comparator. Hence, in the base-case, M + P is the main comparator, in 
accordance with the TROPIC trial design. In addition, an indirect comparison 
versus P alone was carried out. Costs in added life years were added in the model 
to follow the societal perspective of Swedish health care system. RESULTS: In 
the base case analysis, total costs were estimated to be 699 176 SEK for 
Cabazitaxel, 320 491 SEK for M+P and 302 726 SEK for P alone. For the TROPIC 
subgroup, the ICER for C+P vs M+P was 943 270 SEK/QALY, ICER for C+P vs P 
alone was 990 903 SEK/QALY . Based on historical decision making by TLV, the 
threshold in Sweden is 1,000,000 SEK/QALY. CONCLUSIONS: Cabazitaxel appears 
to be a cost effective option compared with mitoxantrone and prednisone in the 
subgroup of TROPIC in Swedish health care setting.  
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OBJECTIVES: To evaluate the cost-effectiveness of posaconazole versus 
fluconazole/ itraconazole in invasive fungal infection (IFI) prevention among 
patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes 
(MDS) and at high risk of IFI due to chemotherapy-induced neutropenia in 
Singapore. METHODS: A decision-analytic model previously developed for the US 
and other countries was adapted to Singapore, to estimate the cost-effectiveness 
of antifungal prophylaxis with posaconazole compared to fluconazole/ 
itraconazole among AML or MDS patients at high risk of IFI. Patients were 
assumed to receive prophylaxis with posaconazole or fluconazole/ itraconazole. 
Probabilities of IFI, IFI-related death, and other cause death within 100 days of 
follow-up were estimated from clinical trial data. Trial results were extended to a 
lifetime horizon by modeling cancer-specific mortality, estimated from 
published sources, in one-month Markov cycles. Prophylaxis and IFI treatment 
costs were estimated using data obtained from two hospitals in Singapore. Model 
